Bone Biologics is a publicly traded company based in Burlington, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1 provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.
Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
Board of Directors
Bruce Stroever, Chairman
President and CEO, Musculoskeletal Transplant Foundation (MTF)
Bruce Stroever has served as a Chairman of the Bone Biologics Board of Directors since 2012. Stroever has forty years of product development and general management experience in the medical device and orthobiologics fields. He is currently the President and Chief Executive Officer of MTF. He was General Manager of MTF from 1988 until 1996, when he became CEO. From 1971 to 1988, prior to joining MTF, Stroever held several positions with Ethicon, Inc., a Johnson & Johnson, Inc. subsidiary. Stroever currently serves on the advisory boards for the Department of Bioengineering at UCLA and the New Jersey Organ and Tissue Sharing Network.
John Booth, Director
John Booth has been CEO of Spineology Inc. since 2004 and has been a board member since its inception in 1998. He held various executive level positions at Phillips Plastics Corporation, most recently serving as CEO from 2001 to 2002. He was CEO of Microvena Corporation, a cardiovascular device subsidiary of Phillips, from 1999 to 2001 and CEO of Phillips Origen Group Division from 1998 to 1999. Prior to Phillips, Booth was President and CEO of INCSTAR Corporation, a publicly held medical technology company involved in in-vitro diagnostics. He has held various positions in both financial and general management in the medical technology industry since 1981. Booth earned a B.S. in accounting from Villanova University and an M.B.A. from Seton Hall University.
Bret Hankey, Director
President, Hankey Group
Mr. Hankey brings more than 15 years of operating and board director experience to the BBLG board. Since 2000, Mr. Hankey has served in various capacities within the Hankey Group where he currently serves as President and is a member of the board of directors on all seven operating companies specializing primarily in the automotive, finance, technology, real estate and insurance industries.
Jimmy Delshad, Director
Chairman, Delshad Capital and Goodwill Ambassador, City of Beverly Hills
Jimmy Delshad is Chairman of Delshad Capital, which guides companies in technology, security, crowd funding and marketing. He served as Mayor and Councilmember of the City of Beverly Hills from 2003-2011, managing a budget of approximately $500 million and more than 1,000 city employees. From 2011-2012, Delshad was Vice Chairman at Pacific Capital Group and served as Founder and CEO of American International Business, Inc. from 1978-2002. He served on the Board of Directors of Evryx Corp from 2008-2010 and Dream Team Gaming from 2007-2009. Delshad received his B.S. in Computer Science from California State University and completed additional post-graduate coursework at the University of Southern California.
Stephen R. La Neve, Director
CEO and President, Bone Biologics
Steve La Neve brings thirty years of health care experience, leadership and success with leadership roles in the device and diagnostic segments which include: CEO and president of Etex Corporation; president of Becton Dickinson’s Pre-Analytical Systems business; president of Medtronic’s $3.5b Spine and Biologics business; and president of Medtronic’s second largest country business unit, Medtronic Japan. He was senior vice president and executive vice president at Premier and ran the global Injection Systems business unit for Becton Dickinson. La Neve held a number of commercial leadership roles at Becton Dickinson, Roche Diagnostics and E Merck Diagnostic Systems in sales, marketing, strategic planning and project management. He serves on the board of directors for Bone Biologics, SkelRegen, LLC and Rapid Pathogen Screening, Inc. (RPS), and he consults for private equity companies in the medical device area.
While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.
Bone Biologics was founded in 2004 by Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering.The Company was acquired in 2006 by MTF, the major shareholder and primary funder since the acquisition.
Headquartered in Burlington, Massachusetts, USA, Bone Biologics became a public company in September 2014 and is focused on bone repair and regeneration applications. The company is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
For information regarding our company and/or products, please complete the form below.